Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 20/20 | 0.78 |
| ▸ | CA1 | P00915 | 20/20 | 0.78 |
| ▸ | CA2 | P00918 | 20/20 | 0.78 |
| ▸ | CA9 | Q16790 | 20/20 | 0.78 |
| ▸ | CA7 | P43166 | 19/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 17/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14493373 | 0.88 | CA12 (0.87) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31650449 | 0.84 | CA12 (0.71) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31267062 | 0.81 | MGLL (0.61) | CA12CA1CA2CA9CA7 | |
| SCHEMBL27531642 | 0.81 | CA1 (0.71) | CA12CA1CA2CA9CA7 | |
| SCHEMBL21485402 | 0.79 | CA2 (0.61) | CA12CA1CA2CA9CA7 | |
| Ethylene SCHEMBL8376508 | 0.78 | CA1 (0.68) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2957586 | 0.78 | CA12 (0.61) | CA12CA1CA2CA9CA7 | |
| SCHEMBL10983933 | 0.78 | ACHE (0.71) | CA12CA1CA2CA9CA7 | |
| SCHEMBL1136719 | 0.77 | L3MBTL3 (0.59) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL1136918 | 0.75 | L3MBTL3 (0.58) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | CA12 4263/4885CA1 4483/4885CA2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.